3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Colorectal Neoplasms
40
Colonic Neoplasms
10
Neoplasms
8
Stomach Neoplasms
7
Neoplasm Metastasis
5
Carcinoma, Non-Small-Cell Lung
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Gastrointestinal Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Hepatocellular
3
Unresectable Metastatic Colorectal Cancer
2
Liver Neoplasms
2
Gastrointestinal Diseases
2
Gallbladder Neoplasms
2
Digestive System Neoplasms
2
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Recurrence, Local
1
Melanoma
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Disease Progression
1
Interventions
Gemcitabine
12
Cisplatin
10
pembrolizumab
7
Fluorouracil
7
Leucovorin
6
Oxaliplatin
5
durvalumab
3
Capecitabine
3
zanidatamab
2
Paclitaxel
2
Irinotecan
2
Folfox protocol
2
Bevacizumab
2
vandetanib
1
tucatinib
1
trastuzumab deruxtecan
1
seribantumab
1
merestinib
1
lenvatinib
1
irinotecan sucrosofate
1
galactomannan
1
fludarabine
1
exatecan
1
bintrafusp alfa protein, human
1
becatecarin
1
aldesleukin
1
Trastuzumab
1
Temozolomide
1
Tegafur
1
S 1 (combination)
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Gallbladder Neoplasms
×
Folfox protocol
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts
NCT07265674
2026-05-14
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3
Recruiting
480 enrolled